Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide 7.2 mg in Obesity and Type 2 Diabetes
NCT05649137Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jan 2023
- Primary completion
- Oct 2024
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
A Phase 3 trial of semaglutide in obesity, type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Started Jan 2023; status: completed.
02
Drugs
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05649137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05649137.